Takehiko Nakasato

Dr. Takehiko Nakasato

Showa University
orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 August 2019 in Diagnostics
Verified
Journal Article
Open access
PDF file
NMNaoe Michio
Naoe Michio
CKChiho Kusaka
Chiho Kusaka
MOMika Ohta
Mika Ohta
YHYuki Hasebe
Yuki Hasebe
TUTsutomu Unoki
Tsutomu Unoki
HIHikaru Ishii
Hikaru Ishii
Purpose: Liquid biopsy is becoming increasingly important as a guide for selecting new drugs and determining their efficacy. In urological cancer, serum markers for renal cell and urothelial cancers has made the development of liquid biopsy for these cancers strongly desirable. Liquid biopsy is less invasive than conventional tissue biopsy is, enabling frequent biopsies and, therefore, is considered effective for monitoring the treatment course. Circulating tumor cells (CTCs) are a representative liquid biopsy specimen. In the present study, we focused on developing our novel technology for capturing renal cell cancer (RCC)-CTCs using an anti-G250 antibody combined with new devices. Basic experiments of our technology showed that it was possible to detect RCC-CTC with a fairly high accuracy of about 95%. Also, RCC-CTC was identified in the peripheral blood of actual RCC patients. Additionally, during the treatment course of the RCC patient, change in the number of RCC-CTC was confirmed in one case. We believe that the technology we developed will be useful for determining the treatment efficacy and drug selection for the treatment of renal cell cancer (RCC). In order to solve issues such as thresholds setting of this technology, large-scale clinical trials are expected.

1 January 2020 in Urology Research and Practice
Verified
Journal Article
Closed access
SNSat Prasad Nepal
Sat Prasad Nepal
TNTakehiko Nakasato
Takehiko Nakasato
YOYoshio Ogawa
Yoshio Ogawa
MNMichio Naoe
Michio Naoe
TSTakeshi Shichijo
Takeshi Shichijo
MOMadoka Omizu
Madoka Omizu
Objective: This study aimed to assess the relationship of the prostate cancer and Gleason scores (GSs) or ISUP Grade system with prostate volume (PV) as assessed by magnetic resonance imaging (MRI) cognitive biopsy and standard biopsy. Material and methods: Data were collected from 659 patients who underwent MRI cognitive biopsy and standard biopsy from January 2014 to January 2018. The biopsies were performed because of increased prostate-specific antigen (PSA) levels (>4 ng/mL) and/or abnormal digital rectal examination findings. Transrectal ultrasound was used to measure PV. Results: Prostate cancer detection rates in patients with increased PVs of ≤40 cc and >40 cc were 68.8% and 51.6% (p40 cc were 68% and 73%, and 22.3% and 37.8%, respectively, for those with ISUP Grade group ≥4 (Gleason score ≥8) (p=0.003). Among the patients with PV>40 cc, univariate logistic regression showed a significant relationship between ISUP Grade group ≥2 and PSA, free/total PSA, PSA density, and MRI (p40 cc. Conclusion: Although the detection rates of prostate cancer decreased as PV increased, the detection of prostate cancer aggressiveness increased as PV increased. This increase in high ISUP Grade lesions with the rise in PV is due to the use of MRI during prostate biopsy with standard biopsy. Cite this article as: Nepal SP, Nakasato T, Ogawa Y, Naoe M, Shichijo T, Maeda Y, et al. Prostate cancer detection rate and Gleason score in relation to prostate volume as assessed by magnetic resonance imaging cognitive biopsy and standard biopsy. Turk J Urol 2020; 46(6): 449-54.

1 April 2021 in Radiology Case Reports
Verified
Journal Article
Open access
SNSat Prasad Nepal
Sat Prasad Nepal
TSTakeshi Shichijo
Takeshi Shichijo
YOYoshio Ogawa
Yoshio Ogawa
TNTakehiko Nakasato
Takehiko Nakasato
YNYoshihiro Nakagami
Yoshihiro Nakagami
MMMoyuru Mizunuma
Moyuru Mizunuma
Segmental testicular infarction is a rare condition. Patients present with clinical features similar to torsion and testicular tumors, with most undergoing surgery. A 55-year-old male patient presented with left scrotal pain. We did a Doppler ultrasonogram and magnetic resonance imaging to diagnose his condition and rule out testicular torsion and tumor. We decided not to operate and asked the patient for follow-up. There was no pain in the left testis, and magnetic resonance imaging showed a reduction in the left testicular lesion after 4 months.

11 March 2020 in Diagnostics
Verified
Journal Article
Open access
PDF file
TNTakehiko Nakasato
Takehiko Nakasato
CKChiho Kusaka
Chiho Kusaka
MOMika Ota
Mika Ota
YHYuki Hasebe
Yuki Hasebe
KUKumiko Ueda
Kumiko Ueda
YOYoshio Ogawa
Yoshio Ogawa
Background: The AR-V7 splice variant is a cause of castration-resistant prostate cancer (CRPC). However, testing for the presence of AR-V7 by real-time polymerase chain reaction (RT-PCR) shows AR-V7 positivity in healthy individuals. We hypothesized that the positivity reflects contamination by hematopoietic cells. We tried a novel circulating tumor cell (CTC) enrichment instrument, using Celsee, to clear hematopoietic cells. Methods: We tested whole blood or Celsee-enriched samples for AR-V7 by RT-PCR, and included samples from 41 CRPC patients undergoing sequential therapy. We evaluated the associations between AR-V7 status and clinical factors. We evaluated factors affecting AR-V7 positivity. Results: AR-V7 positivity was lower in Celsee-enriched than in whole blood specimens. AR-V7 and clinical factors did not predict the therapy effectiveness. We found no significant differences in the effectiveness of enzalutamide/abiraterone (Enz/Abi) upon AR-V7 evaluation. All AR-V7 positive patients had resistance to Enz/Abi. Docetaxel (DTX), cabazitaxel (CBZ), and Radium223 treatment showed no significant difference in the treatment effectiveness, regardless of AR-V7 presence. AR-V7 was more frequently positive than Extent of disease (EOD) 2 in cases with bone metastases. Conclusion: Celsee CTC enrichment suppresses AR-V7 false positivity. All AR-V7 positive patients presented resistance to Enz/Abi. DTX, CBZ, and Radium223 were effective and remain treatment options. AR-V7 positivity should progressively appear in patients with advanced bone metastases.

16 December 2021 in IJU Case Reports
Verified
Journal Article
Open access
PDF file
TNTakehiko Nakasato
Takehiko Nakasato
TITatsuki Inoue
Tatsuki Inoue
RKRyosuke Kato
Ryosuke Kato
YNYoshihiro Nakagami
Yoshihiro Nakagami
KOKazuhiko Oshinomi
Kazuhiko Oshinomi
TFTakashi Fukagai
Takashi Fukagai
Introduction Patients with metastatic urothelial carcinoma have poor prognosis and limited treatment options. Case presentation The patient was a 60-year-old male with bladder cancer and multiple lung metastases. He underwent three courses of gemcitabine and cisplatin chemotherapy, despite left femoral bone metastases. Tumor resection and bone replacement surgery was performed. Following the administration of four courses of pembrolizumab, lung metastasis completely resolved. However, after nine courses, right femoral neck bone metastasis was observed; therefore, tumor resection and bone replacement surgery were repeated. Pathologically, PD-L1 expression was low in lung biopsy tissue and bone metastases. Pembrolizumab treatment continued for up to 20 courses; cancer recurrence and adverse events were not observed upon follow-up examination after 1 year. Conclusion Patients responding well to systemic therapy may have resectable metastatic sites, and long-term survival might be achieved with adjunctive metastasectomy. The effect of pembrolizumab was not associated with positive PD-L1 expression.

1 April 2021 in Journal of Surgical Case Reports
Verified
Journal Article
Open access
PDF file
SNSat Prasad Nepal
Sat Prasad Nepal
TSTakeshi Shichijo
Takeshi Shichijo
YOYoshio Ogawa
Yoshio Ogawa
TNTakehiko Nakasato
Takehiko Nakasato
YNYoshihiro Nakagami
Yoshihiro Nakagami
MMMoyuru Mizunuma
Moyuru Mizunuma
We present a case of lung adenocarcinoma metastasizing to the right clear cell renal cell carcinoma diagnosed by computed tomography (CT)-guided renal biopsy and immunohistochemistry. A 72-year-old male patient had right lower abdominal pain for 3 days, followed by right loin pain for 10 days. On CT scan, renal cell cancer was suspected with multiple metastases. Renal cell cancer with metastatic lung adenocarcinoma was diagnosed on CT-guided renal biopsy with positive immunohistochemical markers. The patient, unfortunately, expired after few days of diagnosis. Tumor-to-tumor metastasis is an unusual disease, and its tumors are aggressive. A definite diagnosis of tumor-to-tumor metastasis is a clinical challenge. Immunohistochemistry helped us in the diagnosis without the primary lesion biopsy.